Researchers at Lund University identified SLAMF6, a surface protein expressed on acute myeloid leukemia (AML) cells that functions as an immune evasion mechanism by suppressing T cell attack. Using CRISPR-Cas9 gene editing and antibody blockade of SLAMF6, they successfully restored T cell cytotoxicity against AML in vitro and in humanized mouse models. This discovery opens avenues for immunotherapy targeting leukemia-specific antigens that spare healthy hematopoietic cells.